Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Cash from Financing Activities (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Cash from Financing Activities for 3 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 995.89% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $202.5 million through Dec 2025, up 61088.82% year-over-year, with the annual reading at $202.5 million for FY2025, 61088.82% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $8.1 million at Nuvation Bio, up from $501000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $193.4 million in Q2 2025, with the low at -$1.5 million in Q3 2024.
  • Average Cash from Financing Activities over 3 years is $17.0 million, with a median of $215500.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities plummeted 2097.4% in 2024, then skyrocketed 6938.68% in 2025.
  • Over 3 years, Cash from Financing Activities stood at $120000.0 in 2023, then crashed by 850.0% to -$900000.0 in 2024, then skyrocketed by 995.89% to $8.1 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $8.1 million, $501000.0, and $193.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.